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Targeted antiangiogenic agents 
in combination with cytotoxic chemotherapy 
in preclinical and clinical studies in sarcoma
Kieuhoa T. Vo1*, Katherine K. Matthay1 and Steven G. DuBois2
Abstract 
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that 
inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas. 
However, when used as monotherapy in the clinical setting, these targeted antiangiogenic agents have only provided 
modest survival benefits in some sarcoma subtypes, and have not been efficacious in others. Preclinical and early 
clinical data suggest that the addition of conventional chemotherapy to antiangiogenic agents may lead to more 
effective therapies for patients with these tumors. In the current review, the authors summarize the available evidence 
and possible mechanisms supporting this approach.
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Background
Sarcomas are a heterogeneous group of malignancies, 
including soft tissue sarcomas (STS) and tumors of bone 
and cartilage. Conventional chemotherapy regimens for 
advanced or metastatic sarcomas have low survival rates, 
substantial toxicity, and frequent emergence of resist-
ance, making alternative novel treatment approaches a 
priority.
Sarcomas express proangiogenic factors that may rep-
resent therapeutic targets, with vascular endothelial 
growth factor (VEGF) being the best characterized. In 
animal models of human sarcomas, inhibitors of angio-
genesis have shown promising antitumor activity [1–3]. 
Antiangiogenic therapies have a number of potential 
advantages compared to chemotherapy including over-
coming chemoresistance [4, 5], more favorable toxicity 
profile, and broad spectrum of activity. Since 2004, over 
ten drugs that target VEGF or its receptors have been 
approved as cancer therapeutics, with many more in 
clinical trials [6]. These agents have shown single-agent 
activity in sarcoma. Most notably, pazopanib has been 
approved by the US Food and Drug Administration and 
the European Medicines Agency for advanced STS. As 
monotherapy, these agents have only provided survival 
benefits on the order of weeks to months in some sar-
coma subtypes, and have not been efficacious in others 
[7]. Therefore, combining antiangiogenic agents (AA) 
with other systemic agents active in sarcoma may lead to 
more effective therapies for patients with these tumors.
This review summarizes evidence supporting the use 
of targeted AA in combination with cytotoxic chemo-
therapy in sarcomas. We performed an extensive review 
of the available medical literature using the US National 
Library of Medicine’s PubMed search function to find rel-
evant primary articles based on key search terms includ-
ing “angiogenesis”, “antiangiogenic”, “antiangiogenesis”, 
and “antivascular”. These search terms were searched with 
“chemotherapy” and “sarcoma”, “bone tumor”, or “soft tis-
sue cancer”. The “Related Articles” function of PubMed 
and reference lists from relevant articles were used to iden-
tify additional articles. Additionally, in order to identify 
recent trials not yet published, we also performed a search 
of abstracts presented at the American Society of Clinical 
Oncology (ASCO) annual meetings from 2013 to 2015.
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In the current review, we provide the results of this 
search beginning with the preclinical data supporting 
AA in combination with chemotherapy in this diverse 
group of diseases. The review concludes with an assess-
ment of the completed and ongoing clinical studies that 
have treated patients with sarcoma using this therapeutic 
strategy.
Preclinical efficacy of targeted AA in combination 
with chemotherapy
Angiogenesis is tightly regulated at the molecular level. 
Dysregulation of angiogenesis occurs in various patholo-
gies and is one of the hallmarks of cancer. Concentrated 
efforts in this area of research are leading to the discov-
ery of a growing number of pro- and anti-angiogenic 
molecules, many of which are already in clinical trials. 
The complex interactions among these molecules and 
how they affect vascular structure and function in dif-
ferent environments are now beginning to be elucidated 
[6, 8–10]. This integrated understanding is leading to the 
development of a number of therapeutic approaches to 
treat cancer, including the use of AA in combination with 
chemotherapy.
Biological mechanisms supporting combination approaches 
in solid tumor malignancies other than sarcoma
With the discovery of VEGF as a major driver of tumor 
angiogenesis, efforts have focused on novel therapeutics 
aimed at inhibiting VEGF activity. Unfortunately, clinical 
trials of anti-VEGF monotherapy in patients with solid 
tumors have resulted in only modest responses. Intrigu-
ingly, the combination of anti-VEGF therapy with con-
ventional chemotherapy has improved survival in cancer 
patients compared with chemotherapy alone [6].
The proposed mechanisms of benefit from combined 
AA and chemotherapy include: (1) normalization of 
the tumor vasculature by altering vascular permeabil-
ity and increasing drug accessibility (Fig.  1a); (2) syner-
gistic effects leading to enhanced direct cytotoxicity of 
cancer cells and/or endothelial cells (Fig. 1b); and/or (3) 
decreased chemoresistance (Fig. 1c).
A paradoxical hypothesis that may explain the anti-
tumor effect of this combination approach relies on the 
theory of transient “normalization” of the abnormal 
tumor vasculature, which results in improved blood 
perfusion and enhanced chemotherapy accessibility and 
antitumor activity (Fig.  1a) [6]. Several preclinical stud-
ies using direct and indirect AA support the normaliza-
tion hypothesis [11–13]. Blockade of VEGF signaling 
results in transient pruning and active remodeling of 
the immature and leaky blood vessels of tumors in ani-
mal models so that it more closely resembled the normal 
vasculature. Functional improvements accompany these 
morphological changes, including decreased intersti-
tial fluid pressure (IFP), decreased tumor hypoxia, and 
improved penetration of macromolecules from these ves-
sels into tumors [11–13].
Based on this hypothesis, Liu and colleagues examined 
the vascular density and structural changes of tumors 
obtained from lung cancer xenograft mice treated with 
bevacizumab combined with gemcitabine and cisplatin 
[14]. They demonstrated significant reduction in VEGF 
levels and microvessel density (MVD) and increased 
number of normal vessels as analyzed by electron micros-
copy in mice treated with combination therapy compared 
to those mice treated with chemotherapy alone [14]. The 
tumor volume of mice in the combined treatment group 
was significantly lower compared to the bevacizumab 
monotherapy and chemotherapy groups, which also cor-
related with significant survival advantage [14].
Improved chemotherapy delivery secondary to tumor 
vessel normalization was demonstrated in a study of 
bevacizumab and topotecan in neuroblastoma xenograft 
models. After a single bevacizumab dose, there were 
decreases in tumor MVD, tumor vessel permeability, 
and tumor IFP compared to controls [15]. Intratumoral 
perfusion, as assessed by contrast-enhanced ultrasonog-
raphy, was also improved [15]. Moreover, intratumoral 
drug delivery accompanied these changes: penetration of 
topotecan was improved when given 1–3 days after beva-
cizumab, compared to concomitant administration or 
7 days apart, and resulted in greater tumor growth inhi-
bition than with monotherapy or concomitant adminis-
tration of the two drugs [15]. Similarly, the increase in 
antitumor activity of chemotherapy during the transient 
vascular normalization period produced by bevacizumab 
has also been confirmed in animal models of colorectal 
cancer (irinotecan) [16] and melanoma (melphalan) [17].
In vivo [(15)O]H2O positron emission tomogra-
phy (PET) imaging in a mouse model of lung cancer 
showed that treatment with the VEGFR/platelet-derived 
growth factor receptor (PDGFR) inhibitor PTK787 cre-
ated a 7-day window of improved tumor blood flow 
when tumor vessels are transiently normalized [18]. An 
improvement in pericyte coverage and reduced leakiness 
from tumor vessels in xenografts accompanied this nor-
malization phase [18]. Initiation of newer targeted agents 
during this window of vessel normalization also resulted 
in increased drug delivery and apoptotic efficacy of erlo-
tinib, an epidermal growth factor receptor (EGFR) inhibi-
tor [18]. Together, these findings offer strong supportive 
evidence that strategic administration of AA can pro-
mote transient vessel normalization that improves drug 
delivery and efficacy in a range of solid tumors.
In contrast, a study by Van der Veldt et al. in non-small 
cell lung cancer (NSCLC) showed that pretreatment 
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Fig. 1 Proposed biological mechanisms supporting combination antiangiogenesis approaches in sarcoma. a Transient “normalization” of the 
abnormal tumor vasculature by AA results in improved blood perfusion and enhanced chemotherapy accessibility and antitumor activity. b The 
synergistic interaction of combination therapy leads to enhanced direct cytotoxicity of tumor cells and/or endothelial cells. c Combination therapy 
leads to up- or down-regulation signaling pathways involved in chemoresistance. For example, down-regulation of the Wnt/β-catenin pathway by 
the combination of masitinib and gemcitabine contribute to the re-sensitization of gemcitabine-resistant pancreatic tumor cells leading to apop-
totic death [27]. AA antiangiogenic agents
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with bevacizumab reduced both perfusion and net influx 
rate of radiolabeled docetaxel as measured by PET with 
effects persisting after 4 days [19]. This study highlighted 
the importance of drug scheduling and advocated further 
studies to optimize scheduling of antiangiogenic drugs 
combined with cytotoxic chemotherapy.
Other preclinical studies reporting the impact of AA 
upon delivery of cytotoxic therapies include sunitinib, an 
inhibitor of VEGFR and PDGFR, combined with temo-
zolomide in orthotopic glioma models [20, 21]. Sunitinib 
significantly increased temozolomide tumor distribu-
tion [21]. A “vascular normalization index” incorporating 
MVD and protein expression of α-SMA and collagen IV 
was proposed as an indication of the number of tumor 
vessels with relatively good quality, and significantly cor-
related with the unbound temozolomide AUC in tumor 
interstitial fluid [21].
Interestingly, when used as monotherapy, several pre-
clinical studies have shown that the normalization of 
blood vessels by AA may result in paradoxical increased 
invasion of local vessels by the tumor and resulting 
metastases. A recent study of the effects of combination 
therapy in breast cancer model suggest that the addi-
tion of chemotherapy to AA can help prevent local inva-
sion of vessels promoted by the AA and result in lower 
metastatic rate. Antiangiogenic therapy with DC101 
(VEGFR2 inhibitor), while blunting tumor volume 
growth, was found to increase local invasion in multiple 
primary tumor models, including a patient-derived xeno-
graft [22]. This effect was blocked by concurrent chemo-
therapy with paclitaxel [22]. Similarly, the combination 
of paclitaxel with DC101 caused a marked reduction of 
micro- or macrometastatic disease in contrast to DC101 
monotherapy, which was associated with small increases 
in metastatic disease.
Synergistic effects of combination therapy of AA with 
chemotherapy have been seen in several preclinical mod-
els of solid cancers (Fig. 1b). For example, in vitro studies 
of bladder cancer demonstrated the efficacy of pazopanib 
with docetaxel, even in docetaxel-resistant bladder can-
cer cell lines [23]. While the mechanism(s) of these syn-
ergistic effects have not been fully elucidated, and may be 
dependent on the specific combination regimen used and 
tissue type treated, we have highlighted several examples 
of mechanisms related to enhanced direct cytotoxicity of 
cancer cells and/or endothelial cells.
Sorafenib increased apoptosis in melanoma-derived 
cell lines treated with melphalan or temozolomide 
[24]. The molecular mechanisms underlying sorafenib 
enhancement were investigated by analyzing the changes 
in signaling events in melanoma cell lines in response to 
sorafenib treatment alone. Response to sorafenib cor-
related with extracellular signal-regulated kinase (ERK) 
down-regulation and loss of Mcl-1 expression [24]. 
These results suggest that sorafenib enhanced sensitiv-
ity to chemotherapy by altering signaling in the mitogen-
activated protein kinase (MAPK) and the mitochondrial 
apoptotic pathways. These in vitro findings highlight the 
potential for AA to have effects independent of classical 
antiangiogenic mechanisms.
The timing and sequence of AA with chemotherapy 
can also be critical in determination of synergy or 
antagonism. Troiani et al. demonstrated the sequence-
dependent interactions of ZD6474 (VEGR, EGFR, 
and RET inhibitor) with oxaliplatin in colon cancer 
cell lines in  vitro using three combination schedules 
[25]. Treatment with oxaliplatin followed by ZD6474 
was highly synergistic, whereas the reverse sequence 
or concurrent exposure was clearly antagonistic [25]. 
Oxaliplatin induced a G2-M arrest, which was antag-
onized if the cells were previously or concurrently 
treated with ZD6474. ZD6474 enhanced oxaliplatin-
induced apoptosis, but only when added after oxalipl-
atin [25].
Alternatively, Naumova and colleagues demonstrated 
that paclitaxel and SU6668, a VEGFR2/PDGFR inhibitor, 
synergistically inhibited the proliferation and increased 
apoptosis of endothelial cells [26]. These findings, 
together with the in  vivo inhibition of angiogenesis in 
Matrigel plugs and the reduction of MVD of paclitaxel-
resistant ovarian carcinoma xenograft models, support 
the hypothesis that the enhanced effect exerted by the 
combination of paclitaxel and SU6668 on tumor growth 
is mediated by an effect on the vasculature [26].
Another mechanism of combination therapy involves 
overcoming chemoresistance (Fig.  1c). Acquired drug 
resistance is a major problem in the treatment of cancer. 
Boehm et al. reported that chronic, intermittent therapy 
of three different mouse tumors with endostatin, an angi-
ogenic inhibitor, did not show any evidence of acquired 
drug resistance [5]. In contrast, standard chemotherapy, 
using maximum doses of cyclophosphamide, resulted in 
drug resistance in lung carcinoma xenografts [5]. These 
results provided initial evidence that a specific angio-
genic inhibitor does not induce drug resistance in three 
different tumor xenografts. Perhaps the most significant 
finding of this study was that repeated cycles of endosta-
tin therapy induced tumor dormancy that persisted after 
therapy. While the mechanism(s) is not yet clear, recent 
studies may help to elucidate these findings.
For example, a series of in  vitro and in  vivo stud-
ies using preclinical models of human pancreatic can-
cer characterized the synergistic effects of combination 
therapy with gemcitabine with masitinib, a selective 
inhibitor of PDGFR [27]. The masitinib and gemcitabine 
combination synergistically inhibited proliferation of 
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gemcitabine-refractory cell lines [27]. Analysis of gene 
expression profiling of gemcitabine-resistant pancreatic 
cells revealed differences in gene expression unique to 
the masitinib plus gemcitabine combination. The most 
significantly altered pathway involved genes associ-
ated with Wnt/β-catenin signaling [27]. This pathway is 
involved in pancreatic development and re-activation 
has been implicated in pancreatic carcinoma, suggesting 
a mechanism of augmented cell death with combination 
therapy in gemcitabine-resistant cells as compared to 
gemcitabine monotherapy [27].
Preclinical studies of combination approaches in sarcoma
Targeted AA and cytotoxic chemotherapy have been 
combined in several laboratory models of sarcoma, 
mainly STS, as summarized in Table  1. Most notably, 
studies have shown that VEGFR2 blockade by DC101 
combined with chemotherapy inhibits tumor growth, 
metastases, and angiogenesis in STS xenografts [28, 
29]. Combined DC101 and continuous low-dose doxo-
rubicin resulted in more effective growth inhibition of 
STS xenografts compared to either agent alone [28]. 
DC101 plus doxorubicin also enhanced the inhibition 
of tumor angiogenesis and endothelial cell activity, as 
demonstrated by significantly reduced MVD and inhibi-
tion of neovascularization [28]. Additionally, this com-
bination regimen directly exerted enhanced inhibitory 
effects on endothelial cell migration, proliferation, and 
tube-like formation in vitro. Furthermore, the combina-
tion enhanced apoptosis of endothelial cells [28].
To elucidate the role of recombinant human VEGF165 
in STS growth, metastasis, and chemoresistance, Zhang 
and colleagues generated stably VEGF165-transfected 
STS cell lines to study the effect of VEGF overexpres-
sion in vitro and in vivo. VEGF165-transfected xenografts 
formed highly vascular tumors with shorter latency, 
accelerated growth, enhanced chemoresistance, and 
increased incidence of pulmonary metastases [29]. Com-
bined therapy with DC101 and low-dose doxorubicin 
in vivo suppressed the growth of VEGF165-overexpressing 
xenografts, inhibited angiogenesis, increased the vessel 
maturation index, and suppressed tumor cell prolifera-
tion compared to monotherapy-treated mice. The addi-
tion of DC101 induced endothelial cell sensitivity to 
doxorubicin and suppressed the activity of matrix met-
alloproteinases secreted by endothelial cells [29]. These 
results suggested that the antitumor effects of combined 
therapy with DC101 and doxorubicin were secondary to 
tumor-associated endothelial cell growth modulation and 
chemosensitization [29].
Likewise, the enhanced antitumor effects of combina-
tion therapy using low-dose topotecan and pazopanib in 
mouse models of osteosarcoma and rhabdomyosarcoma 
are thought to be related to augmented antiangiogen-
esis [30]. The metronomic administration of pazopanib 
and topotecan in  vitro showed reduction in circulating 
Table 1 Preclinical studies of combination approaches in sarcoma
ASPS alveolar soft part sarcoma, ES Ewing sarcoma, MVD microvessel density, OS osteosarcoma, RMS rhabdomyosarcoma, STS soft tissue sarcoma, VDA vascular-
disrupting agent, VEGF(R) vascular endothelial growth factor (receptor)
Drug combination Sarcoma tumor models Results compared to models treated with chemotherapy alone Reference
Pazopanib + topotecan OS KHOS and RMS RH30 cell lines 
and xenografts
↑ Antitumor and antiangiogenic effects,
↑ Survival,
↓ Circulating endothelial cells and/or endothelial progenitor cells,
↓ MVD
[30]
VDA (OXi4503/CA1P) +  
doxorubicin
EWS xenografts ↑ Antitumor effects
↑ Necrosis
↓ Perfused vasculature
[59]
Bevacizumab + topotecan ASPS xenografts ↑ Antitumor effects compared to bevacizumab monotherapy, but 
not topotecan alone
[60]
Vandetanib + doxorubicin Multiple STS cell lines and xenografts ↑ Antitumor and antiangiogenic effects
↓ Local growth leiomyosarcoma
↓ Lung metastases in fibrosarcoma
[31]
DC101 + doxorubicin Multiple STS cell lines and xenografts 
transfected with VEGF165
↑ Antitumor and antiangiogenic effects
↓ Tumor growth and pulmonary metastases
↓ MVD
↑ Percentage of mature vessels
↓ Matrix metalloproteinases secreted by endothelial cells
[29]
DC101 + doxorubicin Leiomyosarcoma SKLMS-1 and RMS 
RD cell lines and xenografts
↑ Antitumor and antiangiogenic effects
↓ MVD and neovascularization
↑ Apoptosis of endothelial cells
↓ Endothelial cell migration, proliferation, tube-like formation
[28]
TNP-470 + etoposide Angiosarcoma ISOS-1 cell line and 
xenograft
↑ Antitumor effects
↑ Growth inhibition
[61]
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endothelial cells, circulating endothelial progenitor cells, 
and tumor MVD which correlated with antitumor activ-
ity and enhancement in survival compared with mono-
therapy agents in all preclinical models [30].
Concomitant use of a dual VEGFR2/EGFR inhibi-
tor (vandetanib) with doxorubicin resulted in additional 
cytotoxicity and endothelial cell growth inhibition with 
lowered doxorubicin doses compared to vandetanib 
monotherapy in leiomyosarcoma, fibrosarcoma, and 
uterine sarcoma models [31]. In addition, vandetanib in 
combination with low-dose doxorubicin resulted in sig-
nificant inhibition of human fibrosarcoma xenograft lung 
metastases compared to control and doxorubicin-only 
groups [31]. Collectively, these studies suggest that AA 
plus chemotherapy regimens may also help to reduce 
the dose and therefore cumulative toxicities of cytotoxic 
chemotherapy.
Clinical efficacy of targeted AA in combination 
with chemotherapy
Clinical studies of combination approaches in solid tumors
Outside the field of sarcoma, AA have been combined 
with chemotherapy with varying outcomes. A retrospec-
tive study of patients with advanced solid malignancies 
treated on phase 1 protocols between 2004 and 2013 
showed that chemotherapy concomitant with VEGF(R) 
inhibitors was associated with significantly higher odds 
ratio for clinical benefit compared with chemotherapy 
without VEGF(R) inhibitors [32].
For example, in lung, breast, and colorectal carci-
noma, AA have shown increased activity when combined 
with standard chemotherapy, as highlighted below. In 
advanced non-small cell lung cancer, a randomized phase 
2 trial showed a trend towards increased response rate 
and time to progression when bevacizumab was com-
bined with paclitaxel and carboplatin [33]. Several large 
randomized trials in patients with metastatic breast 
cancer showed significantly higher response rates and 
increased progression-free survival (PFS) when treated 
with bevacizumab combined with chemotherapy com-
pared to those treated with chemotherapy alone [34–38].
Perhaps the disease in which bevacizumab has had the 
greatest impact in combination with chemotherapy is 
metastatic colorectal cancer. After a randomized phase 
2 study showed encouraging results when bevacizumab 
was combined with fluorouracil and leucovorin [39], a 
randomized phase 3 trial of irinotecan, fluorouracil, and 
leucovorin with bevacizumab or placebo showed that 
bevacizumab increased response rate, time to progres-
sion, and overall survival [40]. Given these findings, beva-
cizumab is now included in the first-line management of 
patients with metastatic colorectal cancer. These clinical 
findings provided proof of principle of additive activity 
when AA are added to chemotherapy in patients with 
cancer and support clinical investigation in sarcoma.
Clinical studies of combination approaches in sarcoma
Targeted AA and chemotherapy have been combined 
in numerous early phase clinical trials in children and 
adults with advanced solid tumors. Phase 1 studies 
that included patients with sarcoma are summarized in 
Table  2. The backbone chemotherapy regimens used in 
these trials included taxane- and platinum-based thera-
pies, camptothecins, and gemcitabine. Although not 
powered to evaluate the antitumor activity of AA com-
bined with chemotherapy, the results of these phase 1 
studies suggest that these regimens are generally well tol-
erated with promising clinical activity in sarcomas. In a 
phase 1b study of the combination of bevacizumab added 
to gemcitabine and docetaxel in patients with advanced 
STS, the overall response rate observed was 31  %, with 
5 complete and 6 partial responses, and 18 patients with 
stable disease lasting for a median of 6 months [41]. Sev-
eral pediatric phase 1 clinical trials have demonstrated 
the safety of combining AA, specifically bevacizumab, 
with cytotoxic chemotherapy in patients with advanced 
solid tumors, with tumor responses in patients with 
Ewing sarcoma [42]. In addition to those listed in Table 2, 
combination antiangiogenic approaches combining AA 
and conventional chemotherapy, such as ifosfamide and 
doxorubicin, studied in other malignancies, may warrant 
further study in sarcoma [43, 44].
There have been four reported phase 2 studies evalu-
ating the combination of AA with chemotherapy in 
sarcoma. The combination of bevacizumab with doxo-
rubicin was evaluated in 17 patients with metastatic STS 
[45]. While two partial responses (12 %) were observed, 
this response rate was not greater than that observed 
for single-agent doxorubicin [45]. However, 11 patients 
(65  %) had stable disease lasting four cycles or longer, 
suggesting that further consideration of this treatment 
regimen may be warranted in STS [45]. In general, the 
toxicity of bevacizumab and doxorubicin was similar 
to that reported for single-agent doxorubicin with one 
notable exception: the reported 35  % rate of grade 2 or 
higher cardiotoxicity with this combination regimen 
was greater than expected (compared to historical con-
trols) [45]. Despite close monitoring and standard use 
of dexrazoxane, the observed cardiac toxicity warrants a 
change in the dose and/or schedule in future studies of 
this combination.
The Children’s Oncology Group (COG) evaluated bev-
acizumab or temsirolimus in combination with vinorel-
bine (V) and cyclophosphamide (C) in a randomized 
phase 2 study in patients with advanced rhabdomyosar-
coma. Both treatment regimens were well tolerated and 
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without unexpected toxicities. In a preliminary report, 
patients randomized to VC plus temsirolimus had a 
superior event-free survival compared to VC plus beva-
cizumab (65 vs. 50  %, respectively) [46]. As a VC alone 
arm was not included in the trial, it is not known if 
bevacizumab improved outcomes compared to the VC 
backbone.
Ray-Coquard and colleagues examined the addition 
of bevacizumab added to paclitaxel in a randomized 
phase 2 study of patients with angiosarcoma. While the 
combination antiangiogenic regimen was shown to be 
active in patients with angiosarcoma, the PFS and over-
all survival was similar in both arms [47]. Nevertheless, 
there was increased toxicity in the bevacizumab arm, 
which included one fatal drug-related toxicity (intestinal 
obstruction) [47]. The lack of benefit from bevacizumab 
may be due in part to key mutations in angiosarcoma 
that may activate the proangiogenic pathway indepen-
dently of the classic ligand-receptor activation shown in 
recent studies. These findings suggest that the extracel-
lular blockade of VEGF by a monoclonal antibody, such 
as bevacizumab, would not interfere with angiosarcoma 
proliferation [47]. Given these findings, the authors did 
not recommend the addition of bevacizumab to pacli-
taxel for the treatment of advanced angiosarcoma.
Recently, the Spanish Group for Research on Sarcomas 
presented their findings of a phase 2 study of sorafenib 
and ifosfamide in 35 patients with advanced STS [48]. 
This combination antiangiogenic regimen had accept-
able toxicity in patients previously treated with anthracy-
clines. The study met its primary endpoint requiring at 
least 19/35 patients to be free of progression at 3 months. 
The combination was shown to be active in patients with 
advanced STS. Six (17 %) patients had partial responses 
Table 2 Completed phase 1 (or pilot) trials of combination approaches that enrolled patients with sarcoma
a Only includes SD, PR, and CR responses among patients with sarcoma. CR complete response; DRSCT desmoplastic small round cell tumor; ES Ewing sarcoma; 
GIST gastrointestinal stromal tumor; MPNST malignant peripheral nerve sheath tumor; OS osteosarcoma; PDGFR platelet-derived growth factor receptor; PR partial 
response; RMS rhabdomyosarcoma; STS soft tissue sarcoma; SD stable disease; VEGF(R) vascular endothelial growth factor (receptor)
Drug combination Sarcoma tumor type (number enrolled) Responsesa Reference
Trials with bevacizumab
 Bevacizumab + pegylated SN-38 (EZN-2208) STS (5) SD (2) [62]
 Bevacizumab + bendamustine Angiosarcoma (1) None [63]
 Bevacizumab + irinotecan RMS (1) None [64]
 Bevacizumab + vincristine/irinotecan/temozolomide STS (3); OS (2); ES (1) SD (2) [65]
 Bevacizumab + vincristine/irinotecan/temozolomide ES (2); RMS (1); Clear cell sarcoma (1) CR (1); PR (1) [42]
 Bevacizumab + sorafenib + cyclophosphamide OS (2); RMS (2); Other STS (4) PR (1); SD (3) [66]
 Bevacizumab + gemcitabine/doxetaxel STS (36) CR (5); PR (6); SD (18) [41]
 Bevacizumab + ifosphamide/etoposide/carboplatin STS (7); OS (3); Chondrosarcoma (2); Undifferentiated (1) PR (4); SD (5) [67]
Trials with VEGFR and PDGFR inhibitors
 Pazopanib + cisplatin Sarcoma (5) CR (1); SD (2) [68]
 Pazopanib + topotecan STS (6); OS (2) Unknown [69]
 Pazopanib + ifosfamide Sarcoma (19) PR (3) [70]
 Pazopanib + paclitaxel/carboplatin OS (1); Giant cell tumor (1); Other sarcoma (1) None [71]
 PDGFR inhibitor (CP-868,596) + docetaxel ± axitinib ES (3); Other sarcoma (5) SD (3) [72]
 Semaxanib + cisplatin/irinotecan GIST (2); STS (1) None [73]
 Sorafenib + irinotecan OS (4); Synovial sarcoma (1); DSRCT (1); MPNST (1) Unknown [74]
 Sunitinib + pemetrexed/carboplatin Synovial sarcoma (1) None [75]
 Sunitinib + gemcitabine OS (1); STS (1) SD (1) [76]
 Sunitinib + ifosfamide ES (2); STS (6); Other sarcoma (7) PR (2); SD (3) [77]
 Sunitinib + irinotecan OS (1); STS (1) None [78]
 Sunitinib + docetaxel OS and STS (unknown) None [79]
Trials with other antiangiogenic agents
 Ombrabulin (AVE8062) + docetaxel Muscle/bone tumors (5) None [80]
 Thrombospondin-1 mimetic (ABT-510) + gemcitabine/
cisplatin
Sarcoma (1) None [81]
 Thrombospondin-1 mimetic (ABT-510) + 5-FU/leucovorin Synovial sarcoma (1) None [82]
 TNP-470 + paclitaxel/carboplatin Sarcoma (2) None [83]
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to this regimen. The 3-month PFS was found to be 66 % 
(23/35) in patients treated with sorafenib plus ifosfamide, 
which may exceed the 3-month PFS in patients treated 
with ifosfamide alone, thus warranting further investiga-
tion [48].
Additional clinical trials evaluating combination 
therapy with targeted AA and cytotoxic chemotherapy 
in patients with sarcoma are ongoing (Table  3). With 
early promising results, the latest phase 2 trials have 
been largely directed towards pediatric sarcoma. These 
include bevacizumab, cyclophosphamide, and topote-
can in patients with relapsed/refractory Ewing sar-
coma (NCT01492673); and maintenance bevacizumab 
therapy in high-risk Ewing sarcoma and desmoplastic 
small round cell tumor (NCT01946529). Furthermore, 
the COG is actively enrolling patients on a randomized 
phase 2/3 trial of preoperative chemoradiation or preop-
erative radiation plus or minus pazopanib in STS histolo-
gies other than rhabdomyosarcoma (NCT02180867).
In adults, phase 2 studies are evaluating pazo-
panib and topotecan in patients with high-risk sar-
comas (NCT02357810); pazopanib plus gemcitabine 
in advanced STS (NCT02203760, NCT01593748 and 
NCT01532687); pazopanib and paclitaxel in advanced 
angiosarcoma (NCT02212015); sorafenib, epirubicin, 
ifosfamide, and radiotherapy followed by surgery in 
high-risk STS (NCT02050919). Lastly, there is one open 
randomized phase 3 trial evaluating bevacizumab ver-
sus placebo combined with docetaxel and gemicitabine 
in the treatment of advanced uterine leiomyosarcoma 
(NCT01012297).
Outside of the context of formal clinical trials, several 
retrospective case studies/series have also highlighted 
the potential efficacy of these combination regimens. A 
child with transformed malignant angiosarcoma was suc-
cessfully treated with bevacizumab, gemcitabine, and 
docetaxel, which resulted in temporary tumor regression 
with progression free survival of 12  months [49]. Dra-
matic improvement was also seen in another patient with 
inoperable face and neck angiosarcoma who was treated 
with bevacizumab and paclitaxel [50]. In three pediat-
ric patients with Ewing sarcoma or undifferentiated sar-
coma who were treated with bevacizumab, gemcitabine, 
and docetaxel, two patients had a partial response and 
the third patient had stable disease for >6  months [51]. 
Lastly, in a retrospective analysis of 14 patients with 
hemangiopericytomas and malignant solitary fibrous 
tumors who were treated with bevacizmuab and temo-
zolomide, 11 patients (79 %) achieved a partial response, 
with a median time to response of 2.5 months [52].
Extensively reviewed elsewhere [53, 54], metronomic 
chemotherapy is an alternative antiangiogenic strategy, 
involving the application of daily, low-dose chemother-
apy. With this low-dose approach, apoptosis is induced in 
the less frequently dividing endothelial cells rather than 
in the tumor cells [53]. This approach has been used in 
sarcoma with promising results [55–58]. In a feasibility 
study of metronomic cyclophosphamide plus predniso-
lone in 26 elderly patients with inoperable or metastatic 
STS, the response rate was 27 % and the disease control 
rate (responses and stable disease >12  weeks) was 69  % 
[56]. Currently, there are three open phase 1 studies 
examining the combination of bevacizumab or pazopanib 
added to metronomic chemotherapy that may include 
eligible sarcoma patients (Table 3).
Conclusions
Advances in the biology of sarcomas have established the 
critical role of tumor angiogenesis and multiple signaling 
pathways involved in tumor development, growth, and 
therapy resistance. Numerous preclinical studies have 
demonstrated that targeting proangiogenic mechanisms 
Table 3 Ongoing phase 1 (or pilot) clinical trials of combination approaches in sarcoma
DSRCT desmoplastic small round cell tumor; NCT ClinicalTrials.gov Identifier/Number; STS soft tissue sarcoma
Targeted antiangiogenic agent Chemotherapy regimen Tumor type NCT
Bevacizumab Doxorubicin/temsirolimus Advanced solid tumors, including sarcoma 00761644
Bevacizumab Doxorubicin Advanced Kaposi sarcoma 00923936
Bevacizumab Gemcitabine/docetaxel/valproic acid Advanced sarcoma 01106872
Bevacizumab Gemcitabine/paclitaxel Advanced solid tumors, including sarcoma 01113476
Bevacizumab Irinotecan/temozolomide + standard alkylator-
based chemotherapy
Newly diagnosed DSRCT 01189643
Bevacizumab Metronomic doxorubicin + radiation Resectable STS 01746238
Bevacizumab Metronomic cyclophosphamide/valproic acid/
temsirolimus
Advanced solid tumors, including sarcoma 02446431
Pazopanib Gemcitabine Advanced leiomyosarcoma 01442662
Pazopanib Docetaxel/gemcitabine Operable STS 01719302
Pazopanib Metronomic topotecan Advanced solid tumors, including sarcoma 02303028
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in combination with cytotoxic chemotherapy may pro-
vide a valid approach to overcoming chemoresistance and 
inhibiting growth of these tumors. Early clinical data are 
still inconclusive, but some reports suggest that the use of 
these AA in combination with chemotherapy may be ben-
eficial in the treatment of patients with advanced sarcoma.
Similar to various targeted therapeutic approaches that 
looked straightforward initially, antiangiogenesis has 
turned out to be more complex and nuanced than origi-
nally thought. Although VEGF seems to have a critical 
role in angiogenesis, our knowledge of the other molecu-
lar determinants of angiogenesis is still in its infancy. In 
fact, many of these pro- and antiangiogenic molecules 
are context- and dose-dependent. Additional studies are 
needed to understand these mechanisms and expand 
these findings to determine how to optimize these strate-
gies for use in the management of patients with sarcoma. 
Ultimately, randomized studies are needed to demon-
strate the benefit of angiogenesis inhibitors combined 
with chemotherapy.
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